1-Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29(6):781-8.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759-67
2-engauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396(6712):643-9.
3-Liu Y, Sun H, Hu M, Zhang Y, Chen S, Tighe S, Zhu Y. The role of cyclooxygenase-2 in colorectal carcinogenesis. Clinical colorectal cancer. 2017 Sep 1;16(3):165-72.
4-Stolfi C, De Simone V, Pallone F, Monteleone G. Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int J Mol Sci 2013;14(9):17972-85.
5-Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol 2009;44 Suppl 19:72-6.
6-Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005;7(4):R422-35.
7-Salimi M, Esfahani M, Habibzadeh N, Aslani HR, Amanzadeh A, Esfandiary M, et al. Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. J Environ Pathol Toxicol Oncol 2012;31(4):349-56.
8-Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, et al. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013;13:273.
9-Wu QB, Sun GP. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World Journal of Gastroenterology: WJG. 2015 May 28;21(20):6206.
10-Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase-1 and −2 in human colorectal cancer. Cancer Res. 1995, 55: 3785-3789.
11-Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994, 107: 1183-1188.
12-Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K: Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterology. 2006, 12: 1336-1345
13-Brown JR, DuBois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005, 23: 2840-2855
14-Mehta S, Boddy A, Johnson T, Rhodes M: Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther. 2006, 24: 1321-1331. 10.1111/j.1365-2036.2006.03119.x
15-Liu X, Li P, Zhang ST, You H, Jia JD, Yu ZL: COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus. 2008, 21: 9-14.
16-Li X, Kong L, Liao S, Lu J, Ma L, Long X. The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2017 Jan;23(1):28
17-VEnkAtAChAlA S, RAjEndRAn M. Correlation of COX-2 Expression in Colorectal Carcinoma with Clinicopathological Features. Turkish Journal of Pathology. 2017 Sep 1;33(3):228-34.
18-Chen ZK, Ouyang ZT. Relationship between carcinoembryonic antigen and cyclooxygenase 2 expression and colorectal cancer. Ai zheng= Aizheng= Chinese journal of cancer. 2003 Feb;22(2):164-7.
)